Ibrutix is the Global First Generic Ibrutinib. An orally bioavailable, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
Benefit of Ibrutix:
Ibrutinib is considered by many experts to be a ‘breakthrough treatment’ in some types of lymphoma. It gives higher response rates compared with other second-line therapies for the same types of lymphoma.
Ibrutinib comes as a capsule to take by mouth. It is usually taken once daily. Patient should take Ibrutinib at around the same time every day. Patient must follow the directions on his/her prescription label carefully, and ask doctor or pharmacist to explain any part he/she does not understand. Patient should take Ibrutinib exactly as directed. Patient should not take more or less of it or take it more often than prescribed by his/her doctor.
Patient should swallow the capsules whole with a full glass of water; she/he should not open, break, or chew them.
Doctor may decrease the dose of Ibrutinib during treatment. This depends on how well the medication works for patient and the side effects patient experience. Patient should talk to doctor about how he/she is feeling during treatment. Patient should continue to take Ibrutinib even if he/she feels well. Patient should not stop taking Ibrutinib without talking to doctor.
GLOBAL PATIENT SUPPORT PROGRAM
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
REGISTERED & LICENSED BY REGULATORY AUTHORITY OF BANGLADESH
Ibrutix is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh.
Ibrutix Capsules :-
Drug Administration Registration Number: 341-317-010
Inclusion Date: 07-08-2017 Valid up to: 06-08-2022